Company news
Replimune Group, Inc. news in 2023
Replimune Group, Inc.'s news releases, calls and decks from 2023, newest first.
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
December 4, 2023
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
November 7, 2023
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
November 6, 2023
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunoth...
November 2, 2023
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
September 18, 2023
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
August 2, 2023
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
July 30, 2023
Replimune Announces Sander Slootweg will Depart from its Board of Directors
July 19, 2023
Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting
June 5, 2023
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
June 4, 2023
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 2, 2023
Replimune to Present at the Jefferies Global Healthcare Conference
May 31, 2023
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 24, 2023
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
May 17, 2023
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
May 8, 2023
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
February 8, 2023
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
February 6, 2023
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
January 3, 2023
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023